Get the Stockscreener App
87.15
2.13%
-1.90
Pre-market:
86.92
-0.23
-0.26%
Structure Therapeutics Inc Adr stock is traded at $87.15, with a volume of 741.79K.
It is down -2.13% in the last 24 hours and up +29.34% over the past month.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
See More
Previous Close:
$89.05
Open:
$88.48
24h Volume:
741.79K
Relative Volume:
0.49
Market Cap:
$6.16B
Revenue:
-
Net Income/Loss:
$-100.44M
P/E Ratio:
-39.26
EPS:
-2.22
Net Cash Flow:
$-105.32M
1W Performance:
-5.14%
1M Performance:
+29.34%
6M Performance:
+389.61%
1Y Performance:
+183.41%
1-Day Range:
$86.10
$89.39
1-Week Range:
$86.10
$92.00
52-Week Range:
$13.22
$94.90
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
Name
Structure Therapeutics Inc Adr
Sector
Industry
Phone
(650) 457-1978
Address
601 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO
Compare GPCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
87.15 | 6.29B | 0 | -100.44M | -105.32M | -2.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
475.68 | 121.25B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.44 | 78.94B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
847.72 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
346.79 | 46.18B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
350.00 | 38.73B | 4.98B | 69.59M | 525.67M | 0.5197 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-02-25 | Initiated | Citigroup | Buy |
| Feb-28-25 | Initiated | William Blair | Outperform |
| Jan-08-25 | Initiated | Stifel | Buy |
| Dec-04-24 | Initiated | H.C. Wainwright | Buy |
| Sep-23-24 | Initiated | Morgan Stanley | Overweight |
| May-21-24 | Initiated | JP Morgan | Overweight |
| Apr-09-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-19-23 | Initiated | JMP Securities | Mkt Outperform |
| Jul-27-23 | Initiated | Piper Sandler | Overweight |
| May-25-23 | Resumed | Jefferies | Buy |
| Feb-28-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-28-23 | Initiated | Guggenheim | Buy |
| Feb-28-23 | Initiated | Jefferies | Buy |
| Feb-28-23 | Initiated | SVB Securities | Outperform |
View All
Structure Therapeutics Inc Adr Stock (GPCR) Latest News
CCG Wealth Management LLC Sells 140,000 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Head to Head Review: Structure Therapeutics (NASDAQ:GPCR) and Kodiak Sciences (NASDAQ:KOD) - Defense World
Genentech Licensing Deal and Guggenheim Reaffirmation Could Be A Game Changer For Structure Therapeutics (GPCR) - Sahm
Weight Loss Drugs Market Is Crowded But Structure Therapeutics CEO Has A Strategy For It - Benzinga
Structure Therapeutics (NASDAQ:GPCR) Raised to "Strong-Buy" at The Goldman Sachs Group - MarketBeat
Understanding the Setup: (GPCR) and Scalable Risk - Stock Traders Daily
Structure Therapeutics (NASDAQ:GPCR) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
Assessing Structure Therapeutics (GPCR) Valuation After Genentech Deal And Growing Obesity Pipeline Confidence - Sahm
Healthy Returns: Structure Therapeutics CEO on its obesity pill, combinations and future of GLP-1s - CNBC
Goldman Sachs Initiates Structure Therapeutics(GPCR.US) With Buy Rating, Announces Target Price $102 - 富途资讯
Why Structure Therapeutics Stock Is Breaking Out Now - TipRanks
Pacific Heights Asset Management LLC Raises Stake in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Short Interest in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Grows By 23.7% - MarketBeat
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
SG Americas Securities LLC Has $1.11 Million Stake in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Jim Cramer on Structure Therapeutics: "I Don't Want to Touch It" - Finviz
Structure Therapeutics (GPCR) Is Up 26.9% After Strong Obesity Pill Data And $748 Million OfferingWhat's Changed - Sahm
Structure Therapeutics (NASDAQ:GPCR) Shares Gap UpShould You Buy? - MarketBeat
LLY Stock Falls After FDA Reportedly Delays Obesity Drug Ruling - Finviz
Structure Therapeutics Inc. (GPCR) Has Gained Over 130% in 3 Months. Here is Why - Finviz
Watch Structure Therapeutics CEO Stevens on Pipeline Strategy - Bloomberg.com
Structure Therapeutics Stock Surges Amid Positive Analyst Ratings - StocksToTrade
Janney Capital Management LLC Buys New Shares in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
A 10% Owner Of Structure Therapeutics Shed Shares - AOL.com
Structure Therapeutics (NASDAQ:GPCR) Trading 12.2% HigherShould You Buy? - MarketBeat
Price Target Hike Sparks Optimism for Structure Therapeutics - StocksToTrade
Why Structure Therapeutics Shares Are Surging Now - TipRanks
Assessing Structure Therapeutics (GPCR) Valuation After Obesity Trial Progress And Genentech Licensing Deal - Sahm
Structure Therapeutics inks major GLP-1 licensing deal - MSN
The Technical Signals Behind (GPCR) That Institutions Follow - Stock Traders Daily
Can This Stock Double Again in 2026? - Finviz
VKTX Completes Enrollment in Phase I Maintenance Study of Obesity Drug - sharewise.com
Genentech Licensing Deal For Oral Obesity Drug CT-996 Might Change The Case For Investing In Structure Therapeutics (GPCR) - Sahm
H.C. Wainwright Upgrades Structure Therapeutics (GPCR) on Massive Arbitrage Opportunity for Oral GLP-1 - Finviz
Why Structure Therapeutics Shares Are Surging Higher - TipRanks
Roche Clears Obesity Pill Legal Concerns With Structure Patent Agreement - BioSpace
Cantor Fitzgerald reiterates Structure Therapeutics stock rating at Overweight By Investing.com - Investing.com UK
Structure Therapeutics stock gets BMO Capital’s Outperform rating reaffirmed By Investing.com - Investing.com UK
Genentech makes $100M deal with South City neighbor to clear path for GLP-1 weight-loss drug - The Business Journals
Structure Therapeutics (NASDAQ:GPCR) Stock Price Down 6.4%What's Next? - MarketBeat
Voya Investment Management LLC Sells 14,230 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - Defense World
Analysts Are Bullish on These Healthcare Stocks: Palisade Bio (PALI), Centessa Pharmaceuticals (CNTA) - The Globe and Mail
Osaic Holdings Inc. Buys 31,972 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Medical Stocks To Watch TodayDecember 8th - MarketBeat
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Shares Down 3.3%Here's Why - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Stock Price Up 5.2%Here's Why - MarketBeat
Novo Nordisk Wins FDA Nod for Oral Wegovy in Obesity, Stock Up - Eastern Progress
What Awaits These 4 Biotech Stocks That More Than Doubled in 2025 - Finviz
Structure Therapeutics stock price target raised to $90 from $60 at H.C. Wainwright - Investing.com
Structure Therapeutics Inc Adr Stock (GPCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.89%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):